13. April 2023 – Swissmedic has approved the adapted bivalent vaccine “Comirnaty Original / Omicron BA.4-5” (tozinameran / famtozinameran). It covers the Omicron subvariants BA.4 and BA.5 in addition to the original SARS-CoV-2 strain.

For more information, see here.